Oral Cancer Diagnostic Kit - Zila Receives Indefinite OraTest Marketing Authorization In Seven European Countries

Zila, Inc. (NASDAQ:ZILAD) today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has issued an indefinite renewal of the marketing authorization for OraTest®, the company’s proprietary oral cancer diagnostic kit. Under the European Union’s (EU) mutual recognition process, the company expects to receive renewal licenses for member states including Finland, Greece, Luxembourg, The Netherlands, Belgium, the U.K. and Portugal, over the next 30 to 60 days.

More: continued here

Filed under: Cancer on October 29th, 2008